ORIGINAL REPORTING By Sari Harrar, AARP Medical marijuana has been legalized in 33 states, and many medical experts now approve of its use for particular conditions that affect Americans over the age of 50. This year, the AARP Board of Directors considered the emerging evidence suggesting that marijuana is helpful in treating such conditions and symptoms, …
AARP: Your Questions Answered and What We Know Today Read More »
“Senate Bill 1494 requires the Department to establish an advisory council to provide recommendations to the Department regarding medical marijuana testing. The Department is required to submit a report of the advisory council’s findings and recommendations by December 31, 2019.” When SB1494 passed, it passed not only a 2-year mmj cards but passed mandatory testing …
Get Marijuana Patient Card in Arizona Get a medical marijuana card in Arizona by following these 3 simple steps. Get an Arizona Medical Marijuana Card How much does a medical marijuana card cost? There are two fees: – The state charges $150 for a card (which is valid for 2 years). It’s only $75 if on …
Despite the proven benefits of medical marijuana and the low severity of its negative side effects, many studies have found connections between cannabis use in teens and changes in their brain matter. A new study adds another layer to the discussion, suggesting that this might not be entirely true. Published in the journal Drug and …
ASU study suggests cannabis doesn’t change the brain structure of teens Read More »
ORIGINAL REPORTING By Marijuana Business Daily staff FOR MJBizDaily Troubled CannTrust hires an adviser to explore a possible sale, Cresco rebrands its dispensaries, Harvest Health & Recreation hits some regulatory snags in Pennsylvania and Ohio – and more of the week’s top marijuana business news. Amid turbulence, CannTrust seeks ‘strategic alternatives’ To cap off a rough-and-tumble month for …
BY DR. LLOYD COVENS Farm Bill Non-Progress Report CBD and hemp companies hoping for post-Farm Bill clarity got a heavy dose of “we will get to it”–from expected long delays in pending review and rule-making at both the Food and Drug Administration and the US Department of Agriculture. FDA administrator Scott Gottlieb told a Congressional committee that he will …
